Posted by Psydoc on March 13, 2002, at 21:42:38
In reply to Re: Just look. Take it or leave it. SELEGLINE COMBO!!!, posted by Eloy on March 5, 2002, at 4:35:30
Here are a few MEDLINE abstracts on Selegline:
1: Arch Gen Psychiatry 1994 Aug;51(8):607-15
High-dose selegiline in treatment-resistant older depressive patients.
Sunderland T, Cohen RM, Molchan S, Lawlor BA, Mellow AM, Newhouse PA, Tariot PN,
Mueller EA, Murphy DL.Section on Geriatric Psychiatry, National Institute of Mental Health, Bethesda,
Md.BACKGROUND: We examined the effect of high-dose selegiline in 16
treatment-resistant older depressive patients. We hypothesized that selegiline,
at a dosage of 60 mg/d, would be at least partially effective but that the
higher doses would not maintain the monoamine oxidase B selectivity observed
with the lower doses of selegiline. METHODS: Sixteen treatment-resistant
subjects (mean [ SD] age, 65.6 9.3 years) entered a double-blind,
randomized, crossover study of placebo vs 3 weeks of selegiline at a dosage of
60 mg/d. Objective measures of mood and behavior were obtained in all subjects,
and 10 of the subjects underwent repeated lumbar punctures for analysis of
monoamine metabolites in the cerebrospinal fluid. RESULTS: Objective measures of
mood and behavior revealed significant improvement in the Hamilton Depression
Rating Scale score (37.4% decrease), the Global Depression score (22.7%
decrease), and the Brief Psychiatric Rating Scale score (19.3% decrease);
subjective behavioral measures, however, did not show significant improvement
during the 3-week medication trial. Cerebrospinal fluid values revealed a
statistically significant drop in 3-methoxy-4-hydroxyphenylglycol (51%) and
5-hydroxyindoleacetic acid (17%) levels, and there was a significant lowering of
systolic blood pressure on standing (15%), but these changes were not
accompanied by clinical side effects. CONCLUSIONS: Our results suggest that
high-dose selegiline can be an effective antidepressant in treatment-resistant
older depressive patients. While the selegiline dose required has nonselective
monoamine oxidase effects and thus would not be free of possible tyramine
interactions, other advantages suggest that further investigations with
selegiline are warranted in this population.Publication Types:
Clinical Trial
Randomized Controlled TrialPMID: 7519005 [PubMed - indexed for MEDLINE]
2: Arch Gen Psychiatry 1989 Jan;46(1):45-50
A controlled study of the antidepressant efficacy and side effects of
(-)-deprenyl. A selective monoamine oxidase inhibitor.Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T, Frances AJ,
Kocsis JH, Brown RP.Department of Psychiatry, Cornell University Medical College, New York, NY
10021.Monoamine oxidase (MAO) inhibitors are effective antidepressants whose use is
limited because of unwanted side effects and the possibility of a
tyramine-induced hypertensive crisis (cheese reaction). (-)-Deprenyl (the
official nonproprietary name for this substance is selegiline), a selective MAO
type B inhibitor, may be safer and have fewer side effects, but its
antidepressant efficacy is uncertain. A double-blind placebo-controlled study
was carried out in depressed outpatients who were treated with (-)-deprenyl in
an MAO type B selective dose range and at a higher nonselective dose range.
(-)-Deprenyl did not have a statistically significant antidepressant effect
after three weeks of treatment at doses of 10 mg/d. However, after six weeks and
at higher doses (averaging about 30 mg/d for the second three weeks),
(-)-deprenyl was superior to placebo in antidepressant effect with a positive
response rate of 50% vs 13.6% and with a 41% reduction in the Hamilton
Depression Rating Scale mean score vs 10% in the placebo-treated group. No
hypertensive crises were seen. The rate of occurrence of side effects with
(-)-deprenyl was no greater than with placebo. It was concluded that
(-)-deprenyl is an effective antidepressant in a dose range where it is
distinguished by the absence of many of the side effects typical of nonselective
MAO inhibitors.Publication Types:
Clinical Trial
Controlled Clinical TrialPMID: 2491941 [PubMed - indexed for MEDLINE]
3: Biol Psychiatry 1985 May;20(5):558-65
Biochemical effects of L-deprenyl in atypical depressives.
Liebowitz MR, Karoum F, Quitkin FM, Davies SO, Schwartz D, Levitt M, Linnoila M.
To examine the biochemical effects of 10-30 mg/day L-deprenyl, measurement of
24-hr urinary output of phenylethylamine (PEA), 3-methoxy 4-hydroxy
phenylethyleneglycol (MHPG), and L-deprenyl's amphetamine metabolites were
carried out before and during the treatment of atypical depressives. Platelet
monoamine oxidase (MAO) activity was also assessed. With L-deprenyl 10-30
mg/day, the expected MAO B inhibition occurred, as indicated by significant
increase in urinary PEA excretion and virtual disappearance of platelet MAO
activity. Twenty-five to 33% of the daily dose of L-deprenyl was recovered as
urinary methamphetamine or amphetamine. Excretion of MHPG was significantly
decreased with L-deprenyl 10-20 mg/day. Overall, the results suggest that
L-deprenyl's antidepressant effects are mediated by some mechanism other than,
or in addition to, MAO B inhibition.Publication Types:
Clinical TrialPMID: 3921065 [PubMed - indexed for MEDLINE]
4: Br J Psychiatry 1983 May;142:508-11
L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of
depression: a double blind evaluation.Mendlewicz J, Youdim MB.
In a double blind controlled study, 14 affectively ill patients (2 bipolars, 12
unipolars) were randomly allocated to L-Deprenil treatment (an irreversible
selective MAO-B inhibitor without "cheese effect") and 13 patients (3 bipolars,
10 unipolars) to placebo only. Patients on L-Deprenil showed a significantly
greater clinical improvement than placebo patients. A positive relationship was
found between clinical improvement and degree of platelet MAO inhibition in
patients treated with L-Deprenil.Publication Types:
Clinical Trial
Randomized Controlled TrialPMID: 6409196 [PubMed - indexed for MEDLINE]
Best regards . . .
Ivan
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
poster:Psydoc
thread:96388
URL: http://www.dr-bob.org/babble/20020313/msgs/97853.html